2024年前列腺癌诊治进展  

A review of the advancements in the diagnosis and treatment of prostate cancer in 2024

作　　者：赵强[1] 杜鹏[1] Zhao Qiang;Du Peng(Key laboratory of Carcinogenesis and Translational Research(Ministry of Education/Beijing),department of urology,Peking University Cancer Hospital&Institute,Beijing 100142,China)

机构地区：[1]北京大学肿瘤医院暨北京市肿瘤防治研究所泌尿外科,恶性肿瘤发病机制及转化研究教育部重点实验室,北京100142

出　　处：《泌尿外科杂志(电子版)》2025年第1期16-21,共6页Journal of Urology for Clinicians(Electronic Version)

摘　　要：前列腺癌是男性高发恶性肿瘤,我国前列腺癌发病率和死亡率近年来仍呈现增长的趋势,是我国公共卫生领域的重大健康问题。随着疾病认识的加深、诊断技术的进步、药物研发和适用范围的推广、精准诊疗理念的普及,2024年各大学术年会均有诸多相关研究进展,本文将围绕前列腺癌筛查、局限进展性前列腺癌、高危生化复发前列腺癌、转移性激素敏感和去势抵抗前列腺癌等阶段的诊疗进展进行盘点。Prostate cancer is a prevalent malignant tumor among men.In recent years,the incidence and mortality rates of prostate cancer in China continue to rise,posing a significant health issue in the country's public health sector.Due to the advances in disease understanding,diagnostic technology,drug development,and the wider application of precision concepts,numerous related research advancements have been made in 2024.This article reviews the progress in the diagnosis and treatment of prostate cancer,focusing on various stages such as screening,locally advanced,high-risk biochemical recurrence,metastatic hormone-sensitive and castration-resistant prostate cancer.

关 键 词：前列腺癌 筛查 局限进展 生化复发 转移性激素敏感 去势抵抗 

分 类 号：R737.25[医药卫生—肿瘤]